<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39855560</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2253-8089</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Revista espanola de medicina nuclear e imagen molecular</Title><ISOAbbreviation>Rev Esp Med Nucl Imagen Mol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>"Utility of PET/CT with [<sup>18</sup>F] F-fluorocholine in assessing the response to antiandrogenic therapy in patients with prostate cancer.".</ArticleTitle><Pagination><StartPage>500083</StartPage><MedlinePgn>500083</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remnie.2025.500083</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2253-8089(25)00011-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the correlation between response assessment measured by PET/CT with [<sup>18</sup>F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">A retrospective study included patients with CRPC (castration-resistant prostate cancer) and HSPC (hormone sensitive prostate cancer) treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (&#x394;SUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23). Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and &#x394;SUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA. The correlation between PET and PSA was mild (Kendall's tau_b 0.26), and the classification into Responders/Non-responders had only slight agreement (Cohen's kappa 0.30).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sociedad Espa&#xf1;ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quintero</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain. Electronic address: kquintero@clinic.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Radiodiagn&#xf3;stico, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer-Mileo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a M&#xe9;dica, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vas</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Radiodiagn&#xf3;stico, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribal</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Herreros</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a M&#xe9;dica, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tormo-Ratera</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aversa</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a M&#xe9;dica, Hospital &#xc1;lvaro Cunqueiro, Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilaseca</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Urolog&#xed;a, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farr&#xe9;-Melero</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuster</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain; Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Hospital Cl&#xed;nic Barcelona, Barcelona, Spain; Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>grupo de Medicina Nuclear Cl&#xed;nic Barcelona (MNCB)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Med Nucl Imagen Mol (Engl Ed)</MedlineTA><NlmUniqueID>101770941</NlmUniqueID><ISSNLinking>2253-8089</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical><Chemical><RegistryNumber>6029HGL0QP</RegistryNumber><NameOfSubstance UI="C514960">fluorocholine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>93T0T9GKNU</RegistryNumber><NameOfSubstance UI="C540278">enzalutamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>G819A456D0</RegistryNumber><NameOfSubstance UI="C089740">abiraterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>2010-15-3</RegistryNumber><NameOfSubstance UI="D010669">Phenylthiohydantoin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000736">Androstenes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="Y">Positron Emission Tomography Computed Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002794" MajorTopicYN="Y">Choline</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="Y">Androgen Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="Y">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064129" MajorTopicYN="Y">Prostatic Neoplasms, Castration-Resistant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010669" MajorTopicYN="N">Phenylthiohydantoin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000736" MajorTopicYN="N" AutoHM="Y">Androstenes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abiraterona</Keyword><Keyword MajorTopicYN="N">Abiraterone</Keyword><Keyword MajorTopicYN="N">Apalutamida</Keyword><Keyword MajorTopicYN="N">Apalutamide</Keyword><Keyword MajorTopicYN="N">Enzalutamida</Keyword><Keyword MajorTopicYN="N">Enzalutamide</Keyword><Keyword MajorTopicYN="N">Respuesta al tratamiento</Keyword><Keyword MajorTopicYN="N">Treatment response</Keyword><Keyword MajorTopicYN="N">[(18)F] F-fluorocholine</Keyword><Keyword MajorTopicYN="N">[(18)F]F-fluorocolina</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>25</Day><Hour>13</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39855560</ArticleId><ArticleId IdType="doi">10.1016/j.remnie.2025.500083</ArticleId><ArticleId IdType="pii">S2253-8089(25)00011-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39855559</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2253-8089</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Revista espanola de medicina nuclear e imagen molecular</Title><ISOAbbreviation>Rev Esp Med Nucl Imagen Mol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Correlation between metabolic response determined with [<sup>18</sup>F]FDG PET/CT and pathological response after neoadjuvant treatment and surgery in patients with esophageal cancer.</ArticleTitle><Pagination><StartPage>500088</StartPage><MedlinePgn>500088</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remnie.2025.500088</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2253-8089(25)00012-6</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the correlation between the result of the PET/CT study with [<sup>18</sup>F]FDG and the histological outcome in patients with esophageal cancer undergoing chemoradiotherapy and subsequent surgery.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">41 patients (35 men) diagnosed with esophageal cancer during a 10-year interval were retrospectively evaluated. PERCIST criteria and SULpeak (&#x394;SULpeak) variation between pre- and post-treatment PET/CT studies were used. After neoadjuvant treatment and subsequent surgery, histological response and patient survival were determined, correlating the findings with the result of the metabolic study. Different parameters related to patient and tumors lesion characteristics were compared with respect to histologic response. ROC curves and the Kaplan-Meier method were applied for the analysis of prognostic factors and survival curves.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean follow-up was 34.9&#x202f;months, with 21 relapses-progressions and 25 deaths. Significant differences were demonstrated between histologic responses regarding PERCIST criteria and &#x394;SULpeak. Both showed adequate sensitivity and moderate specificity in relation to their histological correlation. No significant differences were found with respect to other parameters studied. Survival analysis showed significantly different progression-free survival curves for the &#x394;SULpeak and histologic outcome.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PERCIST criteria and &#x394;SULpeak differentiated between patients with and without histological response. &#x394;SULpeak and histological results proved to be prognostic factors. The results could help to personalize treatment and, together with other determinations, allow an active surveillance approach could be contemplated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sociedad Espa&#xf1;ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Infante</LastName><ForeName>J R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quir&#xf3;s</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a Radioter&#xe1;pica, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barco</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bejarano</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Anatom&#xed;a Patol&#xf3;gica, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agudo</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a Radioter&#xe1;pica, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baena</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utrera</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dur&#xe1;n</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain. Electronic address: justo.serrano@salud-juntaex.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Med Nucl Imagen Mol (Engl Ed)</MedlineTA><NlmUniqueID>101770941</NlmUniqueID><ISSNLinking>2253-8089</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004938" MajorTopicYN="Y">Esophageal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="Y">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016629" MajorTopicYN="N">Esophagectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C&#xe1;ncer de es&#xf3;fago</Keyword><Keyword MajorTopicYN="N">Esophageal cancer</Keyword><Keyword MajorTopicYN="N">PERCIST</Keyword><Keyword MajorTopicYN="N">PET/CT</Keyword><Keyword MajorTopicYN="N">PET/TC</Keyword><Keyword MajorTopicYN="N">Pathological response</Keyword><Keyword MajorTopicYN="N">Respuesta histol&#xf3;gica</Keyword><Keyword MajorTopicYN="N">SULpeak</Keyword><Keyword MajorTopicYN="N">SULpico</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no type of conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>25</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39855559</ArticleId><ArticleId IdType="doi">10.1016/j.remnie.2025.500088</ArticleId><ArticleId IdType="pii">S2253-8089(25)00012-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349172</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2253-8089</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Revista espanola de medicina nuclear e imagen molecular</Title><ISOAbbreviation>Rev Esp Med Nucl Imagen Mol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Evaluaci&#xf3;n de la fiabilidad y legibilidad de las respuestas de los chatbots como recurso de informaci&#xf3;n al paciente para las exploraciones PET-TC m&#xe1;s communes.</ArticleTitle><Pagination><StartPage>500065</StartPage><MedlinePgn>500065</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remnie.2024.500065</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2253-8089(24)00093-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to evaluate the reliability and readability of responses generated by two popular AI-chatbots, 'ChatGPT-4.0' and 'Google Gemini', to potential patient questions about PET/CT scans.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Thirty potential questions for each of [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-DOTA-SSTR PET/CT, and twenty-nine potential questions for [<sup>68</sup>Ga]Ga-PSMA PET/CT were asked separately to ChatGPT-4 and Gemini in May 2024. The responses were evaluated for reliability and readability using the modified DISCERN (mDISCERN) scale, Flesch Reading Ease (FRE), Gunning Fog Index (GFI), and Flesch-Kincaid Reading Grade Level (FKRGL). The inter-rater reliability of mDISCERN scores provided by three raters (ChatGPT-4, Gemini, and a nuclear medicine physician) for the responses was assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median [min-max] mDISCERN scores reviewed by the physician for responses about FDG, PSMA and DOTA PET/CT scans were 3.5 [2-4], 3 [3-4], 3 [3-4] for ChatPT-4 and 4 [2-5], 4 [2-5], 3.5 [3-5] for Gemini, respectively. The mDISCERN scores assessed using ChatGPT-4 for answers about FDG, PSMA, and DOTA-SSTR PET/CT scans were 3.5 [3-5], 3 [3-4], 3 [2-3] for ChatGPT-4, and 4 [3-5], 4 [3-5], 4 [3-5] for Gemini, respectively. The mDISCERN scores evaluated using Gemini for responses FDG, PSMA, and DOTA-SSTR PET/CTs were 3 [2-4], 2 [2-4], 3 [2-4] for ChatGPT-4, and 3 [2-5], 3 [1-5], 3 [2-5] for Gemini, respectively. The inter-rater reliability correlation coefficient of mDISCERN scores for ChatGPT-4 responses about FDG, PSMA, and DOTA-SSTR PET/CT scans were 0.629 (95% CI&#x202f;=&#x202f;0,32-0,812), 0.707 (95% CI&#x202f;=&#x202f;0.458-0.853) and 0.738 (95% CI&#x202f;=&#x202f;0.519-0.866), respectively (p&#x202f;&lt;&#x202f;0.001). The correlation coefficient of mDISCERN scores for Gemini responses about FDG, PSMA, and DOTA-SSTR PET/CT scans were 0.824 (95% CI&#x202f;=&#x202f;0.677-0.910), 0.881 (95% CI&#x202f;=&#x202f;0.78-0.94) and 0.847 (95% CI&#x202f;=&#x202f;0.719-0.922), respectively (p&#x202f;&lt;&#x202f;0.001). The mDISCERN scores assessed by ChatGPT-4, Gemini, and the physician showed that the chatbots' responses about all PET/CT scans had moderate to good statistical agreement according to the inter-rater reliability correlation coefficient (p&#x202f;&lt;&#x202f;0,001). There was a statistically significant difference in all readability scores (FKRGL, GFI, and FRE) of ChatGPT-4 and Gemini responses about PET/CT scans (p&#x202f;&lt;&#x202f;0,001). Gemini responses were shorter and had better readability scores than ChatGPT-4 responses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was an acceptable level of agreement between raters for the mDISCERN score, indicating agreement with the overall reliability of the responses. However, the information provided by AI-chatbots cannot be easily read by the public.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sociedad Espa&#xf1;ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aydinbelge-Dizdar</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Ankara Etlik City Hospital, Ankara, Turkiye. Electronic address: fnuraydinbelge@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dizdar</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Software Engineering, ASELSAN Inc., Ankara, Turkiye. Electronic address: kydz93@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Med Nucl Imagen Mol (Engl Ed)</MedlineTA><NlmUniqueID>101770941</NlmUniqueID><ISSNLinking>2253-8089</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="Y">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032882" MajorTopicYN="Y">Comprehension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098842" MajorTopicYN="N">Generative Artificial Intelligence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">ChatGPT-4</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer</Keyword><Keyword MajorTopicYN="N">Google Gemini</Keyword><Keyword MajorTopicYN="N">Informaci&#xf3;n para pacientes</Keyword><Keyword MajorTopicYN="N">Inteligencia artificial</Keyword><Keyword MajorTopicYN="N">PET-TC</Keyword><Keyword MajorTopicYN="N">PET/CT</Keyword><Keyword MajorTopicYN="N">Patient information</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>1</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>21</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349172</ArticleId><ArticleId IdType="doi">10.1016/j.remnie.2024.500065</ArticleId><ArticleId IdType="pii">S2253-8089(24)00093-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38365352</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5107</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Radiologia</Title><ISOAbbreviation>Radiologia (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Role of intravoxel incoherent motion (IVIM) imaging in response assessment of hepatocellular carcinoma after transarterial chemoembolization (TACE) - A prospective study.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>31</EndPage><MedlinePgn>23-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rxeng.2023.03.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5107(23)00036-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Response evaluation of hepatocellular carcinoma (HCC) currently is based on arterial phase enhancement which doesn't take into microstructural changes in the tumor after trans-arterial chemoembolization (TACE).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This prospective study was conducted to assess the feasibility and efficacy of intravascular incoherent motion imaging (IVIM) in response evaluation of HCC after TACE. 39 cirrhotic patients with 48 HCC underwent MR imaging 1 week within and 6weeks after TACE. IVIM parameters like Dslow (true diffusion), Dfast (pseudodiffusion), perfusion fraction and ADC were measured prior to and postTACE. The pre and post TACE values in LR-TR (LIRADS - treatment response) nonviable and viable lesions were compared using paired t-tests. ROC curve analysis was done to calculate sensitivity and specificity and propose cut-off values.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Non-viable lesions showed a significant increase in Dslow (1.208&#xa0;&#xb1;&#xa0;0.581 vs 1.560&#xa0;&#xb1;&#xa0;0.494, P-value -.0207) and ADC (1.37&#xa0;&#xb1;&#xa0;0.53 vs 1.65&#xa0;&#xb1;&#xa0;0.4287, P value .016) after TACE. There was also significant decrease in Dfast (33.7&#xa0;&#xb1;&#xa0;10.4 vs 23.75&#xa0;&#xb1;&#xa0;12.13, P value .0005) and f (19.92&#xa0;&#xb1;&#xa0;10.54 vs 12.9&#xa0;&#xb1;&#xa0;10.41, P value .012) values after TACE in non-viable lesions compared to viable lesions. The change in true diffusion had the highest AUC (0.741) among IVIM parameters with greater than 0.075 increase between preTACE and postTACE values having a sensitivity and specificity of 81.8% and 60% respectively for complete response.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IVIM imaging is feasible to assess the response in HCC after TACE. True diffusion is more sensitive and specific than apparent diffusion in evaluating the response.</AbstractText><CopyrightInformation>Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reddy Bursapalle</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Ciencias de la Imagen y Radiolog&#xed;a Intervencionista, Instituto Sreechitra de Ciencias M&#xe9;dicas y Tecnolog&#xed;a, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valakkadaa</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Ciencias de la Imagen y Radiolog&#xed;a Intervencionista, Instituto Sreechitra de Ciencias M&#xe9;dicas y Tecnolog&#xed;a, Trivandrum, India. Electronic address: jineesh174@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayappan</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Ciencias de la Imagen y Radiolog&#xed;a Intervencionista, Instituto Sreechitra de Ciencias M&#xe9;dicas y Tecnolog&#xed;a, Trivandrum, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Radiologia (Engl Ed)</MedlineTA><NlmUniqueID>101770876</NlmUniqueID><ISSNLinking>2173-5107</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016461" MajorTopicYN="Y">Chemoembolization, Therapeutic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Carcinoma hepatocelular</Keyword><Keyword MajorTopicYN="N">Evaluaci&#xf3;n de la respuesta</Keyword><Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword><Keyword MajorTopicYN="N">Imagen de movimiento incoherente intravascular</Keyword><Keyword MajorTopicYN="N">Intravoxel incoherent motion</Keyword><Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">Perfusi&#xf3;n T1</Keyword><Keyword MajorTopicYN="N">Quimioembolizaci&#xf3;n transarterial</Keyword><Keyword MajorTopicYN="N">Resonancia magn&#xe9;tica</Keyword><Keyword MajorTopicYN="N">Response evaluation</Keyword><Keyword MajorTopicYN="N">T1 perfusion</Keyword><Keyword MajorTopicYN="N">Transarterial chemoembolization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>17</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>16</Day><Hour>20</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38365352</ArticleId><ArticleId IdType="doi">10.1016/j.rxeng.2023.03.003</ArticleId><ArticleId IdType="pii">S2173-5107(23)00036-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37030597</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2253-8089</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Revista espanola de medicina nuclear e imagen molecular</Title><ISOAbbreviation>Rev Esp Med Nucl Imagen Mol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.</ArticleTitle><Pagination><StartPage>319</StartPage><EndPage>324</EndPage><MedlinePgn>319-324</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remnie.2023.04.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2253-8089(23)00030-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study evaluates the prognostic role of different [<sup>18</sup>F]FDG PET/CT metabolic response criteria in metastatic breast cancer (MBC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We retrospectively evaluated the data of MBC patients treated with CDK 4/6 inhibitors who underwent an [<sup>18</sup>F]FDG PET/CT scan before starting and during treatment. [<sup>18</sup>F]FDG PET/CT response was assessed with the European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), and whole-body total lesion glycolysis (WBTLG) criteria. Fleiss kappa was computed to assess the agreement between metabolic response criteria. The endpoint of the study was progression-free survival (PFS). PFS data were analyzed by the Kaplan-Meier method and compared using the log-rank test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included sixteen MBC patients who received CDK 4/6 inhibitors therapy. According to PERCIST, partial metabolic response (PMR) was found in seven patients, stable metabolic disease (SMD) in seven patients, and progressive metabolic disease (PMD) in two patients. According to EORTC, PMR was detected in eight patients, SMD in seven patients, and PMD in one patient. According to WBTLG, PMR was found in 10 patients, SMD in four patients, and PMD in two patients. There was a fair agreement between the three criteria. While progression was detected in seven of the patients during follow-up, no progression was detected in nine of them. Kaplan-Meier analysis revealed that the responders according to WBTLG showed significantly longer PFS than non-responders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment response according to WBTLG criteria during treatment appears to be associated with prolonged PFS in patients treated with CDK 4/6 inhibitors for MBC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Sociedad Espa&#xf1;ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xd6;nner</LastName><ForeName>Hasan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Medical Faculty, Selcuk University, Konya, Turkey. Electronic address: hasanonner@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eren</LastName><ForeName>Orhan &#xd6;nder</ForeName><Initials>O&#xd6;</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Medical Faculty, Selcuk University, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rez</LastName><ForeName>Muslu Kaz&#x131;m</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Medical Faculty, Selcuk University, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Farise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Medical Faculty, Selcuk University, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kara Gedik</LastName><ForeName>Gonca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Medical Faculty, Selcuk University, Konya, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Med Nucl Imagen Mol (Engl Ed)</MedlineTA><NlmUniqueID>101770941</NlmUniqueID><ISSNLinking>2253-8089</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008659" MajorTopicYN="Y">Metabolic Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Cyclin-dependent 4/6 kinase therapy</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer de mama</Keyword><Keyword MajorTopicYN="N">Evaluaci&#xf3;n de la respuesta</Keyword><Keyword MajorTopicYN="N">Fluorodeoxyglucose</Keyword><Keyword MajorTopicYN="N">Fluorodesoxiglucosa</Keyword><Keyword MajorTopicYN="N">Positron emission tomography</Keyword><Keyword MajorTopicYN="N">Response assessment</Keyword><Keyword MajorTopicYN="N">Terapia con quinasa 4/6 dependiente de ciclina</Keyword><Keyword MajorTopicYN="N">Tomograf&#xed;a de emisi&#xf3;n de positrones</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>8</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37030597</ArticleId><ArticleId IdType="doi">10.1016/j.remnie.2023.04.001</ArticleId><ArticleId IdType="pii">S2253-8089(23)00030-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35988844</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2253-8089</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Revista espanola de medicina nuclear e imagen molecular</Title><ISOAbbreviation>Rev Esp Med Nucl Imagen Mol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Is adipose tissue metabolic activity a predictor of pathological responses to neoadjuvant treatment in breast cancer.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>15</EndPage><MedlinePgn>10-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.remnie.2022.08.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2253-8089(22)00083-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVE" NlmCategory="OBJECTIVE">Prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer is essential for optimal treatment strategy. The current approach of adjuvant or neoadjuvant treatment is based on the molecular subtype. Obesity may have affected chemotherapy response. This study aims to evaluate the relationship between metabolic activity of adipose tissue (AT) and pathological responses to NAC. And to define the association with body mass index (BMI) and metabolic parameters of standardized uptake value (SUV) of adipose tissue measured by positron emission computed tomography (PET/CT).</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">One-hundred and sixteen consecutive patients with stage II and III breast cancer who underwent PET/CT before receiving NAC, were evaluated in the study. Metabolic parameters of visceral adipose tissue (VAT-SUV), subcutaneous adipose tissue (SAT-SUV), and calculated SUV of visceral-to-subcutaneous ratio (V/S-ratio) were regarded. The relationship between SUV of AT and pathologic response was evaluated from medical records retrospectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Univariate-analysis revealed that good pathological response was significantly associated with clinical stage (P&lt;.001), HER-2 positivity (P&lt;.001), VAT-SUV (P=.037), VAT-density (P=.043) and V/S-ratio (P=.003). In multivariate-analysis clinical stage, HER-2 positivity and V/S-ratio were found to have statistically effect on pathological response. VAT-volume (P&lt;.001), VAT-SUV (P=.016), SAT-volume (P&lt;.001) and SAT-SUV (P&lt;.001) has positive correlation with BMI value. On the other hand, V/S-ratio (P=.039) and SAT-density (P=.003) has negative correlation with BMI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Metabolic activity of AT is associated with BMI and effected chemotherapy responses. LowV/S ratio was associated with high BMI and poor pathological response to NAC. V/S ratio may be a useful marker for the prediction of NAC responses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedad Espa&#xf1;ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dulgar</LastName><ForeName>Ozgecan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Istanbul Medeniyet University, G&#xf6;ztepe Training and Research Hospital, Department of Medical Oncology, Istanbul 34722, Turkey. Electronic address: ozgecandr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibisoglu</LastName><ForeName>Ebru Orsal</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Istanbul Medeniyet University, G&#xf6;ztepe Training and Research Hospital, Department of Nuclear Medicine, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ay</LastName><ForeName>Seval</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istanbul Medeniyet University, G&#xf6;ztepe Training and Research Hospital, Department of Medical Oncology, Istanbul 34722, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uslu</LastName><ForeName>Hatice</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Istanbul Medeniyet University, G&#xf6;ztepe Training and Research Hospital, Department of Nuclear Medicine, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;m&#xfc;&#x15f;</LastName><ForeName>Mahmut</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istanbul Medeniyet University, G&#xf6;ztepe Training and Research Hospital, Department of Medical Oncology, Istanbul 34722, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Med Nucl Imagen Mol (Engl Ed)</MedlineTA><NlmUniqueID>101770941</NlmUniqueID><ISSNLinking>2253-8089</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Actividad metab&#xf3;lica del tejido adiposo visceral y subcut&#xe1;neo</Keyword><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer de mama</Keyword><Keyword MajorTopicYN="N">Metabolic activity of visceral and subcutaneous adipose tissue</Keyword><Keyword MajorTopicYN="N">Predicci&#xf3;n de la respuesta patol&#xf3;gica</Keyword><Keyword MajorTopicYN="N">Prediction of pathological response</Keyword><Keyword MajorTopicYN="N">Response to neoadjuvant chemotherapy</Keyword><Keyword MajorTopicYN="N">Respuesta a la quimioterapia neoadyuvante</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35988844</ArticleId><ArticleId IdType="doi">10.1016/j.remnie.2022.08.003</ArticleId><ArticleId IdType="pii">S2253-8089(22)00083-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>